Anticholinergic bronchodilators in combination

Raymond Pineda, Stephen I. Rennard

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Chronic obstructive pulmonary disease (COPD), which affects approximately 14 million Americans, is the fourth leading cause of death in the United States and is responsible for an estimated US$6.5 billion in direct and indirect costs per year [1,2]. Its usual course is a slow deterioration of lung function and progressive breathlessness with activities. The age-adjusted death rate for COPD rose 71% from 1967 to 1987, and the 10 year mortality rate is about 50%. Bronchodilators form one of the mainstays of therapy in COPD patients. The judicious use of these agents increases airflow and reduces dyspnea in patients with COPD. Patients often experience a reduction in symptoms and improvement in their quality of life. There are several classes of bronchodilators available for the treatment of COPD, each with specific clinical benefits: anticholinergics, short-acting 2 agonists, combination anticholinergic and short-acting 2 agonist, long-acting 2 agonists and methylxanthines. This chapter reviews the use of an anticholinergic (ipratropium bromide) concomitantly with other bronchodilators, focusing on patients with COPD.

Original languageEnglish (US)
Pages (from-to)1281-1287
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume1
Issue number7
DOIs
StatePublished - Jan 1 2000

Fingerprint

Bronchodilator Agents
Cholinergic Antagonists
Chronic Obstructive Pulmonary Disease
Dyspnea
Ipratropium
Mortality
Cause of Death
Quality of Life
Costs and Cost Analysis
Lung
Therapeutics

Keywords

  • Anticholinergic
  • Bronchodilators
  • COPD
  • Inflammation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Anticholinergic bronchodilators in combination. / Pineda, Raymond; Rennard, Stephen I.

In: Expert Opinion on Pharmacotherapy, Vol. 1, No. 7, 01.01.2000, p. 1281-1287.

Research output: Contribution to journalArticle

Pineda, Raymond ; Rennard, Stephen I. / Anticholinergic bronchodilators in combination. In: Expert Opinion on Pharmacotherapy. 2000 ; Vol. 1, No. 7. pp. 1281-1287.
@article{f554caf420f34b4ea4a97286b3812f06,
title = "Anticholinergic bronchodilators in combination",
abstract = "Chronic obstructive pulmonary disease (COPD), which affects approximately 14 million Americans, is the fourth leading cause of death in the United States and is responsible for an estimated US$6.5 billion in direct and indirect costs per year [1,2]. Its usual course is a slow deterioration of lung function and progressive breathlessness with activities. The age-adjusted death rate for COPD rose 71{\%} from 1967 to 1987, and the 10 year mortality rate is about 50{\%}. Bronchodilators form one of the mainstays of therapy in COPD patients. The judicious use of these agents increases airflow and reduces dyspnea in patients with COPD. Patients often experience a reduction in symptoms and improvement in their quality of life. There are several classes of bronchodilators available for the treatment of COPD, each with specific clinical benefits: anticholinergics, short-acting 2 agonists, combination anticholinergic and short-acting 2 agonist, long-acting 2 agonists and methylxanthines. This chapter reviews the use of an anticholinergic (ipratropium bromide) concomitantly with other bronchodilators, focusing on patients with COPD.",
keywords = "Anticholinergic, Bronchodilators, COPD, Inflammation",
author = "Raymond Pineda and Rennard, {Stephen I.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1517/14656566.1.7.1281",
language = "English (US)",
volume = "1",
pages = "1281--1287",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Anticholinergic bronchodilators in combination

AU - Pineda, Raymond

AU - Rennard, Stephen I.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Chronic obstructive pulmonary disease (COPD), which affects approximately 14 million Americans, is the fourth leading cause of death in the United States and is responsible for an estimated US$6.5 billion in direct and indirect costs per year [1,2]. Its usual course is a slow deterioration of lung function and progressive breathlessness with activities. The age-adjusted death rate for COPD rose 71% from 1967 to 1987, and the 10 year mortality rate is about 50%. Bronchodilators form one of the mainstays of therapy in COPD patients. The judicious use of these agents increases airflow and reduces dyspnea in patients with COPD. Patients often experience a reduction in symptoms and improvement in their quality of life. There are several classes of bronchodilators available for the treatment of COPD, each with specific clinical benefits: anticholinergics, short-acting 2 agonists, combination anticholinergic and short-acting 2 agonist, long-acting 2 agonists and methylxanthines. This chapter reviews the use of an anticholinergic (ipratropium bromide) concomitantly with other bronchodilators, focusing on patients with COPD.

AB - Chronic obstructive pulmonary disease (COPD), which affects approximately 14 million Americans, is the fourth leading cause of death in the United States and is responsible for an estimated US$6.5 billion in direct and indirect costs per year [1,2]. Its usual course is a slow deterioration of lung function and progressive breathlessness with activities. The age-adjusted death rate for COPD rose 71% from 1967 to 1987, and the 10 year mortality rate is about 50%. Bronchodilators form one of the mainstays of therapy in COPD patients. The judicious use of these agents increases airflow and reduces dyspnea in patients with COPD. Patients often experience a reduction in symptoms and improvement in their quality of life. There are several classes of bronchodilators available for the treatment of COPD, each with specific clinical benefits: anticholinergics, short-acting 2 agonists, combination anticholinergic and short-acting 2 agonist, long-acting 2 agonists and methylxanthines. This chapter reviews the use of an anticholinergic (ipratropium bromide) concomitantly with other bronchodilators, focusing on patients with COPD.

KW - Anticholinergic

KW - Bronchodilators

KW - COPD

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=0034568814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034568814&partnerID=8YFLogxK

U2 - 10.1517/14656566.1.7.1281

DO - 10.1517/14656566.1.7.1281

M3 - Article

C2 - 11249465

AN - SCOPUS:0034568814

VL - 1

SP - 1281

EP - 1287

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 7

ER -